Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
David Andorsky, MD
Advertisement
Articles by David Andorsky, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Revumenib in R/R NPM1-Mutant AML
2
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
3
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
4
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
5
